Beijing VJTBio Co., Ltd. recently completed a Series B financing, raising over 100 million yuan. The funds will be utilized to strengthen the company’s full industry chain in drugs development by advancing clinical trials , accelerating the construction of the manufacturing site in Zhejiang, and establishing a marketing team.

Founded in 2016 at the Zhongguancun Biopharmaceutical Park in Beijing, VJTBio is a national high-tech enterprise dedicated to biopharmaceuticals research and aspires to become the global leader in veterinary protein drugs. VJTBio is an innovative biopharmaceutical company that develops animal drugs to human-grade standards. Through years of research and development, VJTBio has addressed the global challenge of developing animal protein drugs using mammalian cell expression systems, which is notoriously difficult and costly. The company brings together top talents in R&D, production, management, and marketing within animal pharmaceutical industry. The company is committed to developing safe, natural, and cost-effective animal protein drugs.

VJTBio’s pipeline focuses on three key areas: livestock reproduction, infectious disease prevention and control, and pet diseases. Most of its products are considered as Class I new veterinary drugs in China, and many are also global pioneers. Two of these candidates are expected to complete phase III clinical trials by the end of 2020, with application materials to be submitted to the Ministry of Agriculture for new drug approval. In 2019, VJTBio invested 150 million yuan to build the first GMP-certified manufacturing facility for animal protein drugs. The civil engineering was completed in September, and equipment commissioning and GMP certification are expected to be finalized in 2021.

With the successful completion of this financing round, VJTBio will expedite the construction of its manufacturing site in Zhejiang, transitioning the company from R&D to a comprehensive industry chain of encompassing production and sales. The company will focus on the global animal drug market, valued at hundreds of billions, building its core competitiveness, driving the industry upgrades, and leading the industry development.